RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.
Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.
A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
Carpronium chloride 5% is a hair growth treatment in Japan, considered less effective than minoxidil or finasteride. Some users report moderate success with it, but its efficacy is not well-verified.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
The user has been using finasteride, dutasteride, and RU58841 for hair loss without success and feels extremely uncomfortable with their appearance, including being bald and short. They express deep unhappiness and social isolation. Suggestions from others include adopting stoicism, focusing on personal development, considering a hair system, improving fashion, working out, and seeking therapy for mental health.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The conversation discusses the use of topical finasteride from Hasson and Wong, with claims that none of their 800 users reported side effects. The user expresses skepticism about these claims and seeks others' experiences with the treatment.
RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.
The conversation discusses hair loss treatments, specifically the use of anti-androgens like RU58841 and Pyrilutamide, which are expensive in India. Alternatives like spironolactone and concerns about the effectiveness of finasteride and dutasteride are also mentioned.
Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
Oral finasteride is recommended over topical finasteride for men in the Indian subcontinent, with no reported side effects. Minoxidil and dermarolling are also suggested, while dietary supplements and topical finasteride are deemed less effective.
The user humorously describes trying various hair loss treatments, including minoxidil, finasteride, and RU58841, with a satirical twist involving psychedelic experiences and imaginary entities. They mistakenly used LSD instead of RU58841 and plan to continue experimenting with other substances.
Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.
A 35-year-old man underwent a hair transplant with Dr. Patty at HairTran Clinic in Bangkok, receiving 4,037 grafts primarily for his crown area. The procedure cost 188,700 THB, with an additional 12,000 THB for optional PRP treatment, and he plans to update with progress pictures in a year.
The conversation is about a 20-year-old male considering a topical gel combining finasteride, minoxidil, and tretinoin for hair loss, looking to replace his daily minoxidil with this new treatment. He has seen good regrowth with minoxidil but is nervous about starting finasteride.
Topical spiro's effectiveness on androgens is discussed. User tried oral DUT, oral Min, keto/nizoral, and RU but experienced worsening hair loss and chest pains. Suggestion given to increase dutasteride and oral minoxidil dosage before considering spironolactone.
A user's 60-day progress using minoxidil and finasteride spray, combined with derma stamping, shampooing twice weekly, vitamins, intense conditioning training, and a carnivore/ketovore diet. The most recent post includes pictures of the progress following a haircut and shower, with hair air dried.
The user is using finasteride and minoxidil for hair loss but feels progress is slow and is considering switching to dutasteride after 12 months. They notice minor shedding but are unsure if the medication is stabilizing their hair loss.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.
User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.